Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

from Health and Science https://ift.tt/Ygc0tNJ
https://ift.tt/FVQpWf6
https://ift.tt/R4oV9Y2